inulin
Trade name: inulin
Approved
Apr 30, 1940
Inulin is a water soluble storage polysaccharide used as a prebiotic, fat replacer, sugar replacer, and texture modifier. Inulin is a soluble fiber which is not digested by human enzymes and produces distinctive fiber-alike results on the effectiveness of the gut, thus, lowering the pH of intestine, providing assistance in relieving constipation and increasing stool load or rate. Inulin decrease the risk of many diseases of the intestinal tract, particularly irritable bowel diseases and colon cancer. Inulin products contain mainly short-chain molecules which enhance the sweetness of sucrose up to 35%, thus it is useful to partially replace sucrose molecule’s flavor. Inulin has been proved an attractive applicant as a low-calorie bulking agent in chocolate, mostly in combination with a polyol which replaces sugar contents without any effect on fat contents. Further uses of inulin include colon specific drug administration and stabilizing and adjuvating vaccine formulations. — NCATS
Clinical trial activity
143 trials · 175 clinical orgs · 1 marketing orgs
Earliest trial started Feb 1, 1997 (NCT00167700)
Timeline
Indications
Approved for
Studied for
- Adenomatous Polyposis Coli · Phase 2
- Asthma · Phase 2
- Bacterial Infections · Phase 2
- Binge Drinking · Phase 2
- Binge-Eating Disorder · Phase 1
- Body-Weight Trajectory · Phase 4
- Bone Diseases, Endocrine · Early Phase 1
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Early Phase 1
- Critical Illness · Phase 2
- Cross Infection · Phase 2
- Cystic Fibrosis · Phase 4
- Diabetes Mellitus · Phase 2
- Diabetes Mellitus, Type 1 · Phase 4
- Diarrhea · Phase 3
- Disease Transmission, Infectious · Phase 2
- Dysbiosis · Phase 4
- Febrile Neutropenia · Phase 2
- Halitosis · Phase 2
- Healthy Volunteers · Early Phase 1
- Immune System Diseases · Phase 1/Phase 2
- Infections · Phase 2
- Inflammation · Phase 2
- Intestinal Neoplasms · Early Phase 1
- Iron Deficiencies · Phase 1/Phase 2
- Irritable Bowel Syndrome · Early Phase 1
- Kidney Diseases · Phase 3
- Kidney Failure, Chronic · Phase 2
- Live Birth · Phase 1
- Malnutrition · Phase 3
- Metabolic Syndrome · Phase 4
- Neoplasms · Phase 3
- Neutropenia · Phase 2
- Nutritional and Metabolic Diseases · Early Phase 1
- Nutrition Disorders · Phase 2
- Obesity · Phase 2
- Osteoarthritis, Knee · Phase 2
- Psychotic Disorders · Phase 4
- Renal Insufficiency, Chronic · Phase 1/Phase 2
- Schizophrenia · Phase 4
- Sepsis · Phase 2
- Tongue Diseases · Phase 2
- Typhoid Fever · Early Phase 1
- Urinary Tract Infections · Phase 1
- Vaccines · Early Phase 1
Mechanism of action
- UnclearUnclear
Unclear unclear
Approval history
- approvedApr 30, 1940
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaInulin ↗
- NCATSJOS53KRJ01 ↗
- ChEMBLCHEMBL1201646 ↗
Also known as
- inulin
- inulin
- inulin
- inulin
- inulin
- inulin
- inulin
- inulin
- inulin and sodium chloride
- inulin and sodium chloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07189585 | Phase 2 | Apr 1, 2026 | Department of Veteran Affairs, National Center for Complementary and Integrative Health (NCCIH), Yale University |
| NCT07300553 | Phase 2 | Dec 31, 2025 | Assistance Publique - Hôpitaux de Paris |
| NCT06372249 | Phase 2 | Dec 31, 2025 | National Institutes of Health (NIH), Northern Arizona University, University of Arizona |
| NCT07112248 | N/A | Sep 1, 2025 | Huazhong University of Science and Technology |
| NCT07095426 | N/A | May 20, 2025 | Ball State University |
| NCT07050888 | N/A | May 9, 2025 | Free University of Amsterdam, University of Amsterdam |
| NCT06866262 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2025 | Department of Defense, University of Michigan |
| NCT06823557 | Phase 1 | Feb 28, 2025 | University of Minho, University of Porto |
| NCT06668922 | N/A | Nov 28, 2024 | University of California, Los Angeles |
| NCT06697626 | N/A | Nov 14, 2024 | Biotechnology and Biological Sciences Research Council, Ulster University, University of Auckland, University of Leeds |
| NCT06494137 | N/A | Oct 31, 2024 | Quadram Institute, University of Nottingham |
| NCT06607523 | N/A | Oct 1, 2024 | The Moody Foundation, University of Texas, Galveston |
| NCT06551961 | N/A | Aug 9, 2024 | University of East Anglia, University of Nottingham |
| NCT06528041 | N/A | Aug 1, 2024 | Purdue University |
| NCT06420401 | N/A | May 15, 2024 | Sun Yat-Sen University |
| NCT06404749 | N/A | May 3, 2024 | Future Biome SA |
| NCT06347198 | Early Phase 1 (Phase 1) | Apr 10, 2024 | Huazhong University of Science and Technology |
| NCT06551948 | N/A | Jan 1, 2024 | University of East Anglia, University of Nottingham |
| NCT06291272 | N/A | Oct 15, 2023 | Quadram Institute, University of Nottingham |
| NCT05532488 | N/A | Aug 1, 2023 | University of Belgrade |